Methods for treating APOE4/4-associated disorders

Patent metadata

Field	Value
Publication number	US-12544348-B2
Application number	US-201917046950-A
Country	US
Kind code	B2
Filing date	Apr 12, 2019
Priority date	Apr 12, 2018
Publication date	Feb 10, 2026
Grant date	Feb 10, 2026

Abstract

The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4/4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4/4 genotype by administering bumetanide, and/or instructions and reagents for testing/identifying a subject having an apoE4/4 genotype.

First claim

What is claimed is:

1 . A method of preventing or treating Alzheimer's Disease (AD) in a subject having an apoE4/4 genotype, the method comprising administering a therapeutically effective amount of bumetanide to the subject.

2 . The method of claim 1 , wherein the administering comprises administering bumetanide to the subject at a dose of 0.05 mg/kg/day or less.

3 . The method of claim 2 , wherein the administering comprises administering bumetanide to the subject at a dose of 0.02 mg/kg/day or less.

4 . The method of claim 1 , wherein the bumetanide is formulated as an oral dosage form comprising a pharmaceutically acceptable carrier, and wherein the oral dosage form is administered orally.

5 . The method of claim 4 , wherein the oral dosage form is administered once daily as a capsule, a tablet, a disintegrating tablet or lozenge, or a sachet.

6 . The method of claim 1 , wherein the bumetanide is administered intravenously or parenterally.

7 . The method of claim 1 , wherein the bumetanide is provided in a transdermal patch.

8 . The method of claim 1 , wherein the subject is a mammal.

9 . The method of claim 8 , wherein the mammal is a human.

10 . A method of preventing or treating Alzheimer's Disease in a subject having an apoE4/4 genotype, the method comprising:
a) identifying a subject as having an apoE4/4 genotype; and b) administering a therapeutically effective amount of bumetanide to the subject.

11 . The method of claim 10 , wherein the identifying comprises performing a PCR-based DNA analytic method on a biological sample from the subject.

12 . The method of claim 11 , further comprising isolating the biological sample from the subject.

13 . The method of claim 10 , wherein the administering comprises administering bumetanide to the subject as a dose of 0.05 mg/kg/day or less.

14 . The method of claim 13 , wherein the administering comprises administering bumetanide to the subject as a dose of 0.02 mg/kg/day or less.

15 . The method of claim 10 , wherein the bumetanide is formulated as an oral dosage form comprising a pharmaceutically acceptable carrier, and wherein the oral dosage form is administered orally.

16 . The method of claim 15 , wherein the oral dosage form is administered once daily as a capsule, a tablet, a disintegrating tablet or lozenge, or a sachet.

17 . The method of claim 10 , wherein the bumetanide is administered intravenously or parenterally.

18 . The method of claim 10 , wherein the bumetanide is provided in a transdermal patch.

19 . The method of claim 10 , wherein the subject is a mammal.

20 . The method of claim 19 , wherein the mammal is a human.

Assignees

• Univ California
• The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone
• The J David Gladstone Inst

Inventors

• Huang Yadong
• Taubes Alice
• Nova Phil
• Sirota Marina

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• A61K9/7023

  Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006) · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title